Pharming Group N.V. (PHGN)
Summary
PHGN Chart
Pharming Group N.V. (PHGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharming Group N.V. ever had a stock split?
Pharming Group N.V. Profile
| Biotechnology Industry | Healthcare Sector | Fabrice Chouraqui CEO | XFRA Exchange | NL0010391025 ISIN |
| NL Country | 404 Employees | - Last Dividend | 23 Nov 2016 Last Split | 23 Dec 2020 IPO Date |
Overview
Pharming Group N.V. is a pivotal player in the biopharmaceutical sector, focusing on the development and commercialization of innovative protein replacement therapies and precision medicines tailored for rare diseases. Its operations span across the United States, Europe, and other international markets. The company, which came into being in 1988, has its headquarters nestled in Leiden, the Netherlands. Through its commitment to addressing the unmet medical needs of patients with rare diseases, Pharming Group N.V. has established itself as a trailblazer in its field, underpinned by strategic collaborations with notable entities like Novartis and Orchard Therapeutics plc to further augment its research, development, manufacturing, and commercialization capabilities.
Products and Services
- RUCONEST
RUCONEST stands as Pharming Group’s flagship product, a recombinant C1 esterase inhibitor designed for the treatment of acute attacks in adults and adolescent patients suffering from hereditary angioedema (HAE). This critical therapeutic solution embodies the company’s dedication to providing relief to those afflicted with this rare, debilitating condition.
- Joenja (leniolisib)
Joenja, known by its chemical name leniolisib, represents an oral small molecule PI3Kδ (phosphoinositide 3-kinase delta) inhibitor tailored for patients battling activated phosphoinositide 3-kinase delta syndrome. This innovative treatment underscores Pharming Group’s prowess in the realm of precision medicine, targeting the underlying mechanisms of rare diseases at the molecular level.
- OTL-105
In the pipeline of investigational treatments, OTL-105 emerges as a hopeful contender, an ex-vivo autologous hematopoietic stem cell gene therapy aimed at HAE. Currently under development, OTL-105 is a testament to Pharming Group’s forward-thinking approach to leveraging gene therapy for the treatment of hereditary angioedema, potentially revolutionizing the care paradigm for patients with this rare condition.
